Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro

Małgorzata Kamocka, Marek Rózalski, Urszula Krajewska, Ryszard Wierzbicki, Wojciech P. Mielicki

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Cancer procoagulant (CP) is a cysteine protease produced by fetal and malignant tissues, activating in vitro blood coagulation factor X. It has been demonstrated that CP is able to stimulate blood platelet adhesion to fibrinogen and collagen. The pro-adhesive properties of CP could play an important role in metastatic spread of cancer as well as in primary tumor growth. Effects of anti-CP antibody on the growth of MCF-7 breast cancer cells and on the cells adhesion to vitronectin have been analyzed in vitro. Addition of polyclonal anti-CP antibody to MCF-7 cell culture resulted in 16-18% (P<0.001) decrease in the cells viability as compared with the control (other antibody or no antibody in the culture). Preincubation of MCF-7 cells with anti-CP antibody reduced the cells adhesion to vitronectin. Further addition of purified CP (0.5-8 μg/ml) to the MCF-7 cells preincubated with anti-CP antibody resulted in complete recovery of adhesive properties of the cells. However, when high concentration (16 μg/ml) of CP was added to the sample, only partial recovery of the adhesive properties by the cells was observed. Results of the experiments support the hypothesis that CP is involved in the growth of cancer cells, but its pro-coagulative properties are of secondary importance. One of the possible mechanisms of the interactions between CP and malignant cell could be the regulation of the cell adhesion processes.

Original languageEnglish (US)
Pages (from-to)89-94
Number of pages6
JournalCancer Letters
Volume222
Issue number1
DOIs
StatePublished - May 10 2005

Fingerprint

cancer procoagulant
Vitronectin
MCF-7 Cells
Growth
Factor X
Cysteine Proteases
Antibodies
Cell Adhesion
Adhesives
Fibrinogen
Neoplasms
Fetus
Collagen
Blood Platelets
Cell Culture Techniques
In Vitro Techniques
Breast Neoplasms

Keywords

  • Cancer procoagulant
  • Cell adhesion
  • MCF-7
  • Vitronectin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro. / Kamocka, Małgorzata; Rózalski, Marek; Krajewska, Urszula; Wierzbicki, Ryszard; Mielicki, Wojciech P.

In: Cancer Letters, Vol. 222, No. 1, 10.05.2005, p. 89-94.

Research output: Contribution to journalArticle

Kamocka, Małgorzata ; Rózalski, Marek ; Krajewska, Urszula ; Wierzbicki, Ryszard ; Mielicki, Wojciech P. / Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro. In: Cancer Letters. 2005 ; Vol. 222, No. 1. pp. 89-94.
@article{e14340963bf5412cbe635ca7c7035c40,
title = "Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro",
abstract = "Cancer procoagulant (CP) is a cysteine protease produced by fetal and malignant tissues, activating in vitro blood coagulation factor X. It has been demonstrated that CP is able to stimulate blood platelet adhesion to fibrinogen and collagen. The pro-adhesive properties of CP could play an important role in metastatic spread of cancer as well as in primary tumor growth. Effects of anti-CP antibody on the growth of MCF-7 breast cancer cells and on the cells adhesion to vitronectin have been analyzed in vitro. Addition of polyclonal anti-CP antibody to MCF-7 cell culture resulted in 16-18{\%} (P<0.001) decrease in the cells viability as compared with the control (other antibody or no antibody in the culture). Preincubation of MCF-7 cells with anti-CP antibody reduced the cells adhesion to vitronectin. Further addition of purified CP (0.5-8 μg/ml) to the MCF-7 cells preincubated with anti-CP antibody resulted in complete recovery of adhesive properties of the cells. However, when high concentration (16 μg/ml) of CP was added to the sample, only partial recovery of the adhesive properties by the cells was observed. Results of the experiments support the hypothesis that CP is involved in the growth of cancer cells, but its pro-coagulative properties are of secondary importance. One of the possible mechanisms of the interactions between CP and malignant cell could be the regulation of the cell adhesion processes.",
keywords = "Cancer procoagulant, Cell adhesion, MCF-7, Vitronectin",
author = "Małgorzata Kamocka and Marek R{\'o}zalski and Urszula Krajewska and Ryszard Wierzbicki and Mielicki, {Wojciech P.}",
year = "2005",
month = "5",
day = "10",
doi = "10.1016/j.canlet.2004.09.005",
language = "English (US)",
volume = "222",
pages = "89--94",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro

AU - Kamocka, Małgorzata

AU - Rózalski, Marek

AU - Krajewska, Urszula

AU - Wierzbicki, Ryszard

AU - Mielicki, Wojciech P.

PY - 2005/5/10

Y1 - 2005/5/10

N2 - Cancer procoagulant (CP) is a cysteine protease produced by fetal and malignant tissues, activating in vitro blood coagulation factor X. It has been demonstrated that CP is able to stimulate blood platelet adhesion to fibrinogen and collagen. The pro-adhesive properties of CP could play an important role in metastatic spread of cancer as well as in primary tumor growth. Effects of anti-CP antibody on the growth of MCF-7 breast cancer cells and on the cells adhesion to vitronectin have been analyzed in vitro. Addition of polyclonal anti-CP antibody to MCF-7 cell culture resulted in 16-18% (P<0.001) decrease in the cells viability as compared with the control (other antibody or no antibody in the culture). Preincubation of MCF-7 cells with anti-CP antibody reduced the cells adhesion to vitronectin. Further addition of purified CP (0.5-8 μg/ml) to the MCF-7 cells preincubated with anti-CP antibody resulted in complete recovery of adhesive properties of the cells. However, when high concentration (16 μg/ml) of CP was added to the sample, only partial recovery of the adhesive properties by the cells was observed. Results of the experiments support the hypothesis that CP is involved in the growth of cancer cells, but its pro-coagulative properties are of secondary importance. One of the possible mechanisms of the interactions between CP and malignant cell could be the regulation of the cell adhesion processes.

AB - Cancer procoagulant (CP) is a cysteine protease produced by fetal and malignant tissues, activating in vitro blood coagulation factor X. It has been demonstrated that CP is able to stimulate blood platelet adhesion to fibrinogen and collagen. The pro-adhesive properties of CP could play an important role in metastatic spread of cancer as well as in primary tumor growth. Effects of anti-CP antibody on the growth of MCF-7 breast cancer cells and on the cells adhesion to vitronectin have been analyzed in vitro. Addition of polyclonal anti-CP antibody to MCF-7 cell culture resulted in 16-18% (P<0.001) decrease in the cells viability as compared with the control (other antibody or no antibody in the culture). Preincubation of MCF-7 cells with anti-CP antibody reduced the cells adhesion to vitronectin. Further addition of purified CP (0.5-8 μg/ml) to the MCF-7 cells preincubated with anti-CP antibody resulted in complete recovery of adhesive properties of the cells. However, when high concentration (16 μg/ml) of CP was added to the sample, only partial recovery of the adhesive properties by the cells was observed. Results of the experiments support the hypothesis that CP is involved in the growth of cancer cells, but its pro-coagulative properties are of secondary importance. One of the possible mechanisms of the interactions between CP and malignant cell could be the regulation of the cell adhesion processes.

KW - Cancer procoagulant

KW - Cell adhesion

KW - MCF-7

KW - Vitronectin

UR - http://www.scopus.com/inward/record.url?scp=17444376434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17444376434&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2004.09.005

DO - 10.1016/j.canlet.2004.09.005

M3 - Article

C2 - 15837545

AN - SCOPUS:17444376434

VL - 222

SP - 89

EP - 94

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -